Follow the MAHA Money: Pharmaceutical Donations, Millions in Fundraising and Questions About Corpora

By Dr. Ashaki Nichols
U.S. Politics / Health Policy / Investigative Reporting

WASHINGTON, D.C. — The Make America Healthy Again movement built much of its public identity around challenging pharmaceutical industry influence and demanding greater transparency in American healthcare.

But federal campaign finance records, investigative reporting and financial disclosures reveal that companies operating in pharmaceutical manufacturing, biotechnology, healthcare services and wellness have established financial relationships with organizations and individuals associated with MAHA.

The findings raise an important accountability question: How can a movement that promises to challenge corporate influence ensure that its own fundraising and business relationships do not create similar conflicts?

How Much Money Has MAHA Raised?

The Federal Election Commission identifies MAHA PAC as a registered political committee, with records showing approximately $3.18 million in receipts from January 1, 2025, through August 31, 2026.

The same FEC summary reports approximately $9.89 million in disbursements during that period, reflecting financial activity that cannot be understood simply by comparing current-year contributions and expenditures. The committee began the reporting period with substantial cash reserves.

These figures represent one political committee, not the combined finances of every organization associated with the MAHA movement.

A separate analysis published by physician and MAHA critic Mary Talley Bowden estimates that six MAHA-associated political and nonprofit organizations collectively reported approximately $100.4 million in revenue or receipts during 2024.

That calculation includes organizations with distinct legal structures, such as Children’s Health Defense and the Informed Consent Action Network. It should not be described as money raised by MAHA PAC alone or as a consolidated, audited financial statement.

The distinction matters because nonprofit revenue, political contributions, transfers between affiliated organizations and private business income may overlap or represent entirely different transactions.

Pharmaceutical and Healthcare Businesses Appear Among PAC Contributors

Campaign finance data compiled from FEC filings identifies several contributors associated with pharmaceutical manufacturing, biotechnology and healthcare services.

Among the reported contributors during the 2025–2026 election cycle are:

The listed contributions total $133,000.

The amounts are drawn from an FEC-derived donor compilation available as of November 8, 2026. They should be reconciled against the underlying transaction records before final publication.

These companies and organizations do not all perform the same functions. Some manufacture or develop medical products, while others provide services or engage in healthcare policy advocacy.

Their contributions demonstrate financial relationships with the political committee, but they do not independently establish that the donors received favorable regulatory decisions.

A Wellness Company Emerges as a Major Donor

One of the largest reported MAHA PAC contributors is Botanic Tonics LLC, which gave $1 million through two $500,000 contributions in March and April 2026.

The company sells a kratom-and-kava beverage marketed under the Feel Free brand.

Botanic Tonics is not a conventional pharmaceutical manufacturer. Its inclusion is nevertheless significant because the company operates in a market affected by federal and state decisions concerning product safety, ingredients and regulation.

The contribution illustrates how businesses outside traditional pharmaceutical manufacturing may have financial interests in health-related policymaking.

The presence of a large contribution does not establish an improper arrangement. It does, however, create a legitimate reason to examine the donor’s regulatory interests and any relevant policy decisions.

The $100 Million Fundraising Ambition

MAHA PAC leader Tony Lyons has publicly discussed a goal of raising $100 million to support political candidates aligned with the movement.

That figure represents a fundraising objective, not verified completed fundraising.

Reporting by The Wall Street Journal and POLITICO has examined Lyons’ network of political committees, nonprofit organizations and business activities.

Critics within the movement have questioned whether corporate fundraising and political spending priorities reflect the interests of grassroots supporters.

Supporters of the strategy argue that building political influence requires fundraising, organizational infrastructure and support for candidates willing to advance health-policy reforms.

The disagreement concerns how those resources should be raised, disclosed and deployed.

Corporate Sponsorships Raise Additional Questions

Beyond political donations, MAHA-associated events have attracted corporate sponsors.

Reporting about a September 2026 summit organized by Lyons identified sponsors including Walmart and major artificial intelligence companies.

These sponsorships are distinct from donations to MAHA PAC.

Nevertheless, they illustrate how businesses seeking visibility or access may become involved with organizations that promote government policy changes.

Critics have questioned whether such relationships undermine the movement’s stated opposition to corporate influence.

Event sponsorship alone does not demonstrate that a company purchased access to a federal official or influenced a regulatory decision.

Establishing such an arrangement would require additional evidence concerning payments, meetings, communications and government actions.

Financial Interests Within MAHA’s Leadership Network

Questions about corporate influence also extend to prominent individuals associated with the movement.

In February 2026, consumer advocacy organization Public Citizen published an investigation examining the business relationships of wellness entrepreneur Casey Means, her brother Calley Means and other figures associated with MAHA.

The report identified sponsorship arrangements, consulting fees, investments and promotional relationships involving companies selling supplements, health testing and wellness products.

Public Citizen reported that Casey Means had financial relationships with multiple businesses whose products she promoted.

Its review identified 79 instances among 140 promotional mentions in which the organization concluded that sponsorship relationships were not adequately disclosed.

Public Citizen also raised concerns about potential conflicts involving Calley Means’ company TrueMed and his government advisory work.

These findings represent Public Citizen’s analysis and allegations. They do not establish that the Federal Trade Commission has determined that the individuals violated federal law.

The Means siblings and other MAHA-associated entrepreneurs have defended their business activities and their broader efforts to reform American healthcare.

Could MAHA-Associated Businesses Benefit From Government Policy?

Financial Times reporting in 2026 examined businesses positioned to benefit from potential changes in federal policy concerning peptides, wellness products and medical treatments.

The report identified companies with connections to MAHA-associated investors and political figures, including pharmaceutical businesses interested in expanding access to certain peptide products.

The potential market opportunities are significant, but financial benefit must be distinguished from improper influence.

A company may support a policy because it believes the change would benefit patients, because it expects commercial growth, or for both reasons.

Determining whether a conflict exists requires examining the decision-making process and the financial interests of participating officials.

Federal regulators have maintained that their decisions are based on applicable scientific and regulatory standards.

Even MAHA Insiders Are Raising Concerns

The financial controversy has become part of a broader disagreement within the movement.

In November 2026, former administration adviser Calley Means publicly alleged that corporate lobbying and political fundraising considerations had interfered with MAHA policy priorities.

His statements, discussed in reporting by STAT and the Associated Press, included allegations concerning food-industry influence and pesticide regulation.

White House officials and other individuals named in the dispute denied the accusations.

The competing accounts demonstrate the extent of internal disagreement but do not independently establish that a particular donor caused a specific government decision.

What the Financial Records Establish—and What They Do Not

The available evidence supports several findings.

MAHA-associated political organizations have raised and spent substantial sums. Businesses operating in pharmaceutical, biotechnology, healthcare and wellness markets appear among the financial contributors. Some prominent movement figures also have private commercial interests in health-related businesses.

Those relationships warrant examination, especially when organizations publicly promise to reduce corporate influence over government.

However, the evidence reviewed for this article does not establish that the MAHA movement as a whole has been secretly financed by major pharmaceutical manufacturers, that all affiliated organizations share the same donors, or that specific government decisions were purchased.

Such conclusions would require more complete financial records and evidence directly connecting payments to official actions.

Following the Money Requires More Transparency

For MAHA supporters and critics alike, the central issue is whether the movement’s financial practices align with its public commitments.

A thorough accounting would identify the donors to each political committee, disclose corporate sponsorship arrangements, distinguish nonprofit funding from private business revenue, and examine whether individuals participating in government decisions have relevant financial interests.

It would also require transparency about how money is spent and whether funds intended to advance public health reforms are being used for their stated purposes.

The question is not simply how much money MAHA has raised. It is who supplied the money, who received it, and whether the public can independently evaluate the movement’s financial relationships.